



DRUG DISCOVERY

Biopartnering Strategies

Maximizing returns from biotechnology deal-making

By Steven Seget

 [Table of Contents](#)

Steven Seget

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA from the London Business School. sseget@delphipharma.com

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the portfolio management, business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. www.delphipharma.com

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Biopartnering Strategies

Executive Summary	8	
Biopartnering trends	8	
Licensing across the biotechnology lifecycle	9	
The biopartnering process	10	
Biopartnering for ‘pioneer’ companies	11	
Biopartnering for ‘growth’ companies	12	
Biopartnering for ‘consolidation’ companies	13	
Chapter 1	Biopartnering trends	16
Summary		16
Introduction		17
A maturing biotechnology industry		18
A shift in biopartnering trends		21
Strategic implications		25
Chapter 2	Licensing across the biotechnology lifecycle	28
Summary		28
Introduction		29
The biotech company lifecycle		29
‘Pioneer’ companies		34
‘Growth’ companies		36
‘Consolidation’ companies		37

Chapter 3 The biopartnering process 42

Summary	42
Introduction	43
Biopartnering complexity	43
The biopartnering process	45
Biopartnering strategy	47
Opportunity identification	49
Biotechnology out-licensors	49
Biopartnering in-licensors	53
Licensing evaluations	56
Deal-making and agreement	61
Post-deal management and analysis	65

Chapter 4 Biopartnering for 'pioneer' companies 70

Summary	70
Introduction	71
Biopartnering objectives	71
Case study: IDM Pharma	72
History	72
Financials	73
Key collaborations	75
Medarex	75
Sanofi-Aventis	75
Other key events	76
Jenner Biotherapies	76
Epimmune	76
Pharmexa	76
Recommendations	76

Chapter 5 Biopartnering for 'growth' companies 80

Summary	80
Introduction	81
Biopartnering objectives	81

Case study: Millennium Pharmaceuticals	82
History	82
Financials	83
Key collaborations	85
Sanofi-Aventis	85
Integrilin	86
Ortho Biotech	86
Other key events	87
Leukosite	87
COR Therapeutics	87
Velcade launch	87
Recommendations	88

Chapter 6 Biopartnering for 'consolidation' companies 90

Summary	90
Introduction	91
Biopartnering objectives	91
Case study: Biogen IDEC	92
History	92
Financials	93
Key collaborations	95
Schering AG	95
Elan	96
PDL BioPharma	96
Other key events	96
Biogen IDEC merger	96
Conforma Therapeutics	97
Fumapharm	97
Recommendations	97

Chapter 7 Appendix 100

Primary research survey	100
Index	103

List of Figures

Figure 1.1:	Number of biotechnology M&A deals by partner, 1996-2005	22
Figure 1.2:	Biopartnering by in-licensing partner, 1996-2005	23
Figure 1.3:	Biopartnering by stage of development, 1996-2005	24
Figure 2.4:	Evolutionary growth stages for biotech companies	30
Figure 2.5:	Biotech company growth drivers	31
Figure 2.6:	Key biotech company growth phases	33
Figure 2.7:	The biotechnology industry split by development phase	34
Figure 3.8:	Expected change in number of biopartnering deals over next 12 months	44
Figure 3.9:	Expected change in value of biopartnering deals over next 12 months	44
Figure 3.10:	Expected change in number of potential partners chasing each biopartnering deal over next 12 months	45
Figure 3.11:	The biopartnering licensing process	46
Figure 3.12:	Outside partners involved in identifying potential biopartnering opportunities	53
Figure 3.13:	Outside partners involved in due diligence for potential biopartnering opportunities	60
Figure 3.14:	Key information shared between partners during negotiations over biopartnering agreements	61
Figure 3.15:	Valuation techniques used to support negotiations over biopartnering agreements	62
Figure 3.16:	Outside partners involved in the valuation and negotiation of biopartnering agreements	64
Figure 4.17:	IDM Pharma's revenues, 2005	73
Figure 4.18:	IDM Pharma's key financials, 2000-2005	74
Figure 5.19:	Millennium Pharmaceuticals' revenues, 2005	83
Figure 5.20:	Millennium Pharmaceuticals' key financials, 1994-2005	85
Figure 6.21:	Biogen IDEC's revenues, 2005	93
Figure 6.22:	Biogen IDEC's key financials, 1991-2005	95
Figure 7.23:	Licensing trends survey respondents by company focus	100
Figure 7.24:	Licensing trends survey respondents by functional responsibility	101
Figure 7.25:	Licensing trends survey respondents by licensing responsibility	102

List of Tables

Table 1.1:	The global biotechnology industry by region, 2005	18
Table 1.2:	Growth in the global biotechnology industry, 2004-2005	19
Table 1.3:	Biotechnology equity financing trends in North America and Europe, 2004-2005	19
Table 1.4:	Biotechnology blockbusters, 2003-2005	20
Table 4.5:	IDM Pharma's clinical development pipeline, 2006	74
Table 5.6:	Millennium Pharmaceuticals' clinical development pipeline, 2006	84
Table 6.7:	Biogen IDEC's clinical development pipeline, 2006	94